Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Cognition Therapeutics Inc has 12 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Cognition Therapeutics Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On December 23, 2022, we entered into a sales agreement ("the Previous Sales Agreement") with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. ("B. Riley"), providing for the offering, issuance and sale by us of up to $40.0 million of our common stock from time to time in "at-the-market" offerings (the "2022 ATM").”
FILING10-K0001104659-26-034880cik 0001455365
“On December 23, 2022, we entered into a sales agreement ("the Previous Sales Agreement") with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. ("B. Riley"), providing for the offering, issuance and sale by us of up to $40.0 million of our common stock from time to time in "at-the-market" offerings (the "2022 ATM").”
FILING10-K0001104659-26-034880cik 0001455365
“On March 10, 2023, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park") for an equity line financing (the "Lincoln Park Purchase Agreement").”
FILING10-K0001104659-26-034880cik 0001455365
“Our clinical trials have been funded by approximately $171 million in cumulative grants awarded primarily by the NIA.”
FILING10-K0001104659-26-034880cik 0001455365
“Our clinical trials have been funded by approximately $171 million in cumulative grants awarded primarily by the NIA.”
FILING10-K0001104659-26-034880cik 0001455365
“To date, we have partially relied on the availability of NIA Grants.”
FILING10-K0001104659-26-034880cik 0001455365
“The Lincoln Park Purchase Agreement provides that, subject to the terms and conditions set forth therein, we have the right, but not the obligation, to direct Lincoln Park to purchase up to $35.0 million of shares of common stock at our sole discretion, over a 36-month period commencing on March 10, 2023.”
FILING10-K0001104659-26-034880cik 0001455365
“In December 2025, we entered into a sales agreement with Jefferies LLC, or the Sales Agent, providing for the offering, issuance and sale by us of up to $75 million of our common stock from time to time in "at-the-market" offerings, or the 2025 ATM.”
FILING10-K0001104659-26-034880cik 0001455365
“We are conducting the START clinical trial in collaboration with the Alzheimer's Clinical Trial Consortium, or ACTC, an NIA-funded clinical trials network designed to accelerate studies for therapeutics for AD and related dementias.”
FILING10-K0001104659-26-034880cik 0001455365
“Cognition has received and is reviewing scientific advice from the European Medicines Agency (EMA) indicating a preference for a longer trial than was proposed.”
FILING10-K0001104659-26-034880cik 0001455365
“In work funded by grants from the Michael J. Fox Foundation, α-synuclein oligomers were found to bind to brain cells in culture and are internalized as indicated by the red dots in the image to the left below.”
FILING10-K0001104659-26-034880cik 0001455365
“Zervimesine has continued to be generally well tolerated and has been granted Fast Track designation by the U.S. Food and Drug Administration, or FDA, for AD.”
FILING10-K0001104659-26-034880cik 0001455365
“The United States Adopted Name (USAN) Council adopted zervimesine as the USAN for CT1812 in December 2024.”
FILING10-K0001104659-26-034880cik 0001455365
Watchlist prices, news filtered to it, and its next report on your desk.
Cognition Therapeutics Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 1.04 · gapped below the open, never looked back. High/low 1.04 at 3:45 pm ET, 0.99 at 6:45 am ET.
CGTX (Cognition Therapeutics Inc) has 12 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: RILY −4.17%, in financials.